Analytical performance of lateral flow immunoassay for SARS-CoV-2 exposure screening on venous and capillary blood samples

We validate the use of a lateral flow immunoassay (LFI) intended for rapid screening and qualitative detection anti-SARS-CoV-2 IgM IgG in serum, plasma, whole blood, compare results with ELISA. also seek to establish value LFI testing on blood obtained from capillary sample. Samples collected by venous draw finger stick were patients SARS-CoV-2 detected RT-qPCR control patients. tested Biolidics 2019-nCoV IgG/IgM Detection Kit immunoassay, antibody calls compared showed clinical sensitivity 92% at 7 days after PCR diagnosis SARS-CoV-2. Test specificity was 100% IgG. There no significant difference detecting ELISA D0 D7 (p = 1.00), except 0.04). Capillary 93% detection. Clinical performance is comparable consistent across sample types. This provides an opportunity decentralized may allow point-of-care longitudinal self-testing presence antibodies.